நிறுவனம் மதிப்பீடு கிட் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from நிறுவனம் மதிப்பீடு கிட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In நிறுவனம் மதிப்பீடு கிட் Today - Breaking & Trending Today

Applied DNA and Northwell Health Establish SARS-CoV-2 Mutation and Variant Tracking Program


Published: Apr 07, 2021
 
 - Program Powered by Applied DNA’s Mutation-targeted qPCR Assays and NGS Platform -
- Program Data Potentially Relevant to COVID-19 Vaccine and Therapeutics Developers, Precision Medicine -
 
STONY BROOK & NEW HYDE PARK, N.Y. (BUSINESS WIRE) Applied DNA Sciences, Inc.. (NASDAQ: APDN) (Applied DNA or the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and Northwell Health (Northwell) today announced their entry into a
pro bono Material Transfer Agreement (MTA) that establishes a real-time surveillance program for the tracking and identification of SARS-CoV-2 mutations and variants of concern (VoCs) in Northwell’s COVID-positive specimens (the “Program”). Under the Program, de-identified positive COVID-19 specimens supplied by Northwell are being screened for SARS-CoV-2 mutations found in currently known VoCs using Applied DNA’s Linea ....

New York , United States , Stony Brook , Dwayne Allen Breining , Jamesa Hayward , Northwell Health Is New York , Northwell Health Physician Partners , Company Assay Kit , Hofstra Northwell School Of Nursing , York State Department Of Health , Sciences Inc , Mutation Panel , Northwell Health , Research Use Only , Drug Administration , Northwell Health Labs , Clinical Laboratory Improvement Amendments , Securities Exchange , Feinstein Institutes For Medical Research , Polymerase Chain Reaction , Material Transfer Agreement , Selective Genomic , Assay Kit , New York State , Some Vocs , Genomic Surveillance ,

Applied DNA Sciences, Inc.: U.S. FDA Lists Applied DNA's Linea COVID-19 Assay Kit as 1 of Only 2 EUA-Authorized Tests Able to Detect S-Gene Mutation Found in SARS-CoV-2 U.K. Variant (B.1.1.7)


(2)
- Early and Cost-Effective Identification of Samples Potentially Containing the B.1.1.7 or Other Variants May Help Reduce Further Spread of Infection -
Applied DNA Sciences, Inc. (NASDAQ: APDN) (the Company ), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that the U.S. Food and Drug Administration (FDA) published a safety communication (the Communication ) that identifies the Company s Linea COVID-19 Assay Kit (the Assay Kit ) as one of only two tests marketed under the FDA s Emergency Use Authorization (EUA) that are potentially able to identify certain SARS-CoV-2 mutations, including a mutation found in the U.K. variant of SARS-CoV-2 (B.1.1.7). According to recent publications, the B.1.1.7 variant has been identified within the United States and may be associated with an increased risk of transmission of the virus that causes COVID-19. The identification of certain mutations can help identify samples that should be further ch ....

United States , Jamesa Hayward , Mike Munzer , Sciences Inc , Drug Administration , Company Assay Kit , Clinical Laboratory Improvement Amendments , Company Linea , Securities Exchange , York State Department Of Health , Cost Effective Identification , Samples Potentially Containing , Polymerase Chain Reaction , Use Authorization , Assay Kit , Pooled Surveillance , Russell Microcap , Securities Act , Securities Exchange Act , Private Securities Litigation Reform Act , New York State Department , Emergency Use Authorization , Annual Report , ஒன்றுபட்டது மாநிலங்களில் , அறிவியல் இன்க் , நிறுவனம் மதிப்பீடு கிட் ,